In addition, rising awareness among patients and healthcare providers about the perks of GLP-1 RAs, along with beneficial repayment policies, also accelerates the regional market growth
Several GLP1RAs have received FDA approval for the treatment of type 2 diabetes, including semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide (Table 2)
10.1677/JOE-09-0132 J
All of the patients in the study displayed improved AUD symptoms, both lower alcohol consumption and a desire to drink
Published phase 2 trial data (Jastreboff et al., NEJM, 2023) reported on adverse events in participants receiving retatrutide for obesity
50+ Market leading Companies collaborated with us